Integrated iPSC Technology Platform for Highly Stable MSC and Exosome Manufacturing
Technology Introduction:
Established an iPSC reprogramming platform for disease modeling and drug evaluation, including mitochondrial DNA mutation-associated hearing loss and genetic vision disorders. Differentiated iPSCs into ISCT-compliant mesenchymal stromal cells (iMSCs) and developed proprietary media for iMSC differentiation and iPSC expansion.
Established a highly consistent iPSC-based MSC and exosome manufacturing platform, becoming the first institution in Taiwan to obtain an INCI designation for iPSC-derived exosomes
Industrial Applications:
1. Ensures stable and efficient cell production, enhancing clinical feasibility in regenerative medicine and cell therapy.2. Optimizes cell function through genetic engineering, improving therapeutic efficacy and safety, advancing personalized precision medicine.
3. Establishes an exosome production and analysis platform, addressing market demands in medical aesthetics, pharmaceuticals, and immunotherapy.
4. Standardized and scalable cell manufacturing reduces production costs and increases product accessibility.
Industrial Technology Research Institute
ITRI is a world-leading applied technology research institute with more than 6,500 outstanding employees. Its mission is to drive industrial development, create economic value, and enhance social well-being through technology R&D. Founded in 1973, it pioneered in IC development and started to nurture new tech ventures and deliver its R&D results to industries. ITRI has set up and incubated companies such as TSMC, UMC, Taiwan Mask Corp., Epistar Corp., Mirle Automation Corp., and Taiwan Biomaterial Co.
Contact Information
Name：LIN, MEI-WEI
Tel：0918-131-090
Address：No. 195, Sec. 4, Chung Hsing Rd., Chutung, Hsinchu County 310401, Taiwan (R.O.C.)
